Free tool
FAERS Monitor: Revcovi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761092 or its brand name (Revcovi, Elapegademase-Lvlr). Reports on generic versions are filed under their own applications.
Reports
299
Serious
80
27% of reports
Hospitalization
47
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nasopharyngitis37
- cough23
- covid-1922
- bone marrow transplant13
- pneumonia13
- sinusitis13
- weight decreased12
- pyrexia11
- injection site pain10
- off label use10
- rhinorrhoea10
- diarrhoea8
- product dose omission8
- rash8
- weight increased8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 32 |
| 2020 | 31 |
| 2021 | 20 |
| 2022 | 51 |
| 2023 | 64 |
| 2024 | 57 |
| 2025 | 36 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,860 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone marrow transplantSignal | 13 | 485.6 | 284.8 | 5,772 |
| nasopharyngitisSignal | 37 | 14.1 | 10.4 | 442 |
| rhinorrhoeaSignal | 10 | 10.9 | 5.9 | 80 |
| sinusitisSignal | 13 | 8.9 | 5.2 | 84 |
| covid-19Signal | 22 | 8.8 | 5.9 | 146 |
| product dose omissionSignal | 8 | 8.6 | 4.4 | 47 |
| coughSignal | 23 | 5.8 | 3.9 | 87 |
| weight decreasedSignal | 12 | 3.0 | 1.7 | 14 |
| pneumoniaSignal | 13 | 2.8 | 1.7 | 14 |
| weight increasedSignal | 8 | 2.5 | 1.3 | 6 |
| injection site painSignal | 10 | 2.3 | 1.2 | 6 |
| pyrexiaSignal | 11 | 2.2 | 1.3 | 6 |
| rash | 8 | 1.3 | 0.7 | 0 |
| diarrhoea | 8 | 0.9 | 0.4 | 0 |
| off label use | 10 | 0.8 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.